Sloan Benjamin, Duhaime Erin, Sandkovsky Uriel, Berhe Mezgebe
Texas A&M College of Medicine, College Station, Texas.
Division of Infectious Diseases, Baylor University Medical Center, Dallas, Texas.
Proc (Bayl Univ Med Cent). 2022 Mar 3;35(3):339-341. doi: 10.1080/08998280.2022.2042033. eCollection 2022.
Casirivimab/imdevimab, a cocktail of monoclonal antibodies, is currently approved for emergency use in high-risk ambulatory patients with early COVID-19 to reduce risk of hospitalization and/or death from SARS-CoV-2 infection. In the United States, there is no approved monoclonal antibody therapy for patients hospitalized for complications due to acute SARS-CoV-2 infection. We describe here the use of casirivimab/imdevimab in a 52-year-old fully vaccinated, immunocompromised man admitted to the intensive care unit for acute hypoxemic respiratory failure due to SARS-CoV-2 infection.
卡西瑞单抗/依米德维单抗是一种单克隆抗体鸡尾酒疗法，目前已被批准用于早期新冠病毒疾病（COVID-19）的高危门诊患者，以降低因感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）而住院和/或死亡的风险。在美国，对于因急性SARS-CoV-2感染并发症而住院的患者，尚无获批的单克隆抗体疗法。我们在此描述了卡西瑞单抗/依米德维单抗在一名52岁、已全程接种疫苗但免疫功能低下的男性患者中的应用，该患者因SARS-CoV-2感染导致急性低氧性呼吸衰竭而入住重症监护病房。
